CAPR
Capricor Therapeutics Inc.
$6.51
+$0.30(+4.83%)
55
Overall
60
Value
50
Tech
57
Quality
Market Cap
$304.02M
Volume
1.43M
52W Range
$5.68 - $20.75
Target Price
$20.60
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $5.5M | $4.0M | $2.7M | $1.7M | -- | $310.3K | $244.9K | $2.6M | $25.2M | $22.3M | ||
| Total Revenue | $5.5M | $4.0M | $2.7M | $1.7M | -- | $310.3K | $244.9K | $2.6M | $25.2M | $22.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $5.5M | $4.0M | $2.7M | -- | -- | $310.3K | $244.9K | $2.6M | $25.2M | $22.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-18.1M | $-21.0M | $-15.5M | $-17.0M | $8.7M | $14.0M | $21.2M | $32.2M | $49.3M | $64.8M | ||
| Research & Development | $13.8M | $16.0M | $10.8M | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | ||
| Research Expense | $13.8M | $16.0M | $10.8M | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | ||
| Selling, General & Administrative | $4.4M | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.4M | $12.8M | $14.9M | ||
| General & Administrative Expenses | $4.4M | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.4M | $12.8M | $14.9M | ||
| Salaries & Wages | -- | $-2.0M | $-1.7M | $-1.7M | $-701.0K | -- | -- | -- | $7.4M | $9.8M | ||
| Depreciation & Amortization | -- | $-85.9K | $-95.0K | $-114.4K | $-128.7K | $139.6K | $243.5K | $533.1K | $1.1M | $1.4M | ||
| Depreciation & Amortization | -- | $-85.9K | $-95.0K | $-114.4K | $-128.7K | $139.6K | $243.5K | $533.1K | $1.1M | $1.4M | ||
| Amortization | -- | $-48.7K | $-49.2K | $-43.3K | $-43.3K | $4.3K | $2.2K | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $129.7K | -- | $792.8K | $841.4K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-12.6M | $-17.0M | $-15.5M | $-17.0M | $-8.7M | $-13.7M | $-20.9M | $-29.7M | $-24.1M | $-42.6M | ||
| EBITDA | $-12.5M | $-18.3M | $3.0M | $-15.0M | $-7.5M | $-13.5M | $-20.7M | $-29.2M | $-21.2M | $-39.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $248.6K | $344.7K | $398.8K | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | -- | -- | $15.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-248.6K | $-344.7K | $15.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-3.1K | $1.5M | $-2.7M | $-1.8M | $-1.1M | $-32.9K | $-915.9K | $677.9K | $-1.8M | $-2.1M | ||
| Other Special Charges | $3.1K | $14.4K | $2.7M | $1.8M | $1.1M | $32.9K | $923.8K | $712.1K | $1.8M | $2.2M | ||
| SPECIAL ITEMS | ||||||||||||
| Other Impairment Of Capital Assets | -- | $1.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-12.6M | $-18.5M | $2.8M | $-15.2M | $-7.6M | $-13.7M | $-20.9M | $-29.7M | $-22.3M | $-40.5M | ||
| Pre-Tax Income | $-12.9M | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.1M | $-29.0M | $-22.2M | $-40.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $-12.9M | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | ||
| Net Income (Continuing Operations) | $-12.9M | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | ||
| Net Income (Discontinued Operations) | $-12.9M | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | ||
| Net Income (Common Stockholders) | $-12.9M | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-15.8M | -- | -- | $-40.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-18.1M | $-21.0M | $-15.5M | $-17.0M | $8.7M | $14.0M | $21.2M | $32.2M | $49.3M | $64.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.6M | $1.9M | $2.3M | $2.9M | $3.7M | $15.6M | $23.1M | $24.6M | $26.8M | $35.2M | ||
| Average Shares Outstanding (Diluted) | $1.6M | $1.9M | $2.7M | $2.9M | $3.7M | $15.6M | $23.1M | $24.6M | $26.8M | $35.2M | ||
| Shares Outstanding | $1.8M | $2.1M | $2.8M | $3.4M | $8.9M | $22.8M | $24.3M | $25.3M | $31.4M | $45.7M | ||
| Basic EPS | -- | -- | $1 | -- | -- | $-0.88 | $-0.87 | $-1.18 | $-0.83 | $-1.15 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.88 | $-0.87 | $-1.18 | $-0.83 | $-1.15 | ||
| Diluted EPS | $-8.1 | $-10.1 | $0.90 | $-10.4 | $-2.06 | $-0.88 | $-0.87 | $-1.18 | $-0.83 | $-1.15 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-2.06 | -- | $-0.87 | $-1.18 | $-0.83 | $-1.15 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | $-2.7K | -- | $-7.9K | $-34.3K | $-6.0K | $-112.8K | ||
| Other Gand A | $4.4M | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.4M | $12.8M | $14.9M | ||
| Rent And Landing Fees | $4.4M | $4.9M | $4.8M | $4.9M | $-16.2K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CAPR | $6.51 | +4.8% | 1.43M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Capricor Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW